Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Adicet Bio, Inc.

< Previous 1 2 3 4 Next >
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Appoints Michael Grissinger to the Board of Directors
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.